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Abstract
Background: Porphyrin TMPyP4 (P4) and its C14H28-alkyl derivative (C14) are G-quadruplex binders and singlet
oxygen (1O2) generators. In contrast, TMPyP2 (P2) produces
1O2 but it is not a G-quadruplex binder. As their
photosensitizing activity is currently undefined, we report in this study their efficacy against a melanoma skin
tumour and describe an in vitro mechanistic study which gives insights into their anticancer activity.
Methods: Uptake and antiproliferative activity of photoactivated P2, P4 and C14 have been investigated in murine
melanoma B78-H1 cells by FACS, clonogenic and migration assays. Apoptosis was investigated by PARP-1 cleavage
and annexin-propidium iodide assays. Biodistribution and in vivo anticancer activity were tested in melanoma
tumour-bearing mice. Porphyrin binding and photocleavage of G-rich mRNA regions were investigated by
electrophoresis and RT-PCR. Porphyrin effect on ERK pathway was explored by Western blots.
Results: Thanks to its higher lipophylicity C14 was taken up by murine melanoma B78-H1 cells up to 30-fold more
efficiently than P4. When photoactivated (7.2 J/cm2) in B78-H1 melanoma cells, P4 and C14, but not control P2,
caused a strong inhibition of metabolic activity, clonogenic growth and cell migration. Biodistribution studies on
melanoma tumour-bearing mice showed that P4 and C14 localize in the tumour. Upon irradiation (660 nm, 193 J/cm2),
P4 and C14 retarded tumour growth and increased the median survival time of the treated mice by ~50% (P <0.01 by
ANOVA), whereas porphyrin P2 did not. The light-dependent mechanism mediated by P4 and C14 is likely due to the
binding to and photocleavage of G-rich quadruplex-forming sequences within the 5′-untranslated regions of the
mitogenic ras genes. This causes a decrease of RAS protein and inhibition of downstream ERK pathway, which
stimulates proliferation. Annexin V/propidium iodide and PARP-1 cleavage assays showed that the porphyrins
arrested tumour growth by apoptosis and necrosis. C14 also showed an intrinsic light-independent anticancer
activity, as recently reported for G4-RNA binders.
Conclusions: Porphyrins P4 and C14 impair the clonogenic growth and migration of B78-H1 melanoma cells and
inhibit melanoma tumour growth in vivo. Evidence is provided that C14 acts through light-dependent (mRNA
photocleavage) and light-independent (translation inhibition) mechanisms.
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Background
Photodynamic therapy (PDT) is a rapidly expanding
therapeutic modality for the treatment of a number of
diseases including cancer [1-3]. PDT employs a photo-
sensitizer which, upon irradiation, produces singlet oxy-
gen (1O2) that damages cells [4,5]. One major objective
of PDT is the search of new photosensitizers with high
water solubility, low dark cytotoxycity, high capacity to
penetrate the plasma membrane and generate 1O2, and
an ability to interact with specific cellular targets [6-8].
In previous studies from our laboratory we synthesized
expanded porphyrins, composed of a macrocycle of five
pyrroles, that exhibit a photodynamic activity in cancer
cells at micromolar concentrations, either as free mole-
cules or complexed to Zn or Lu [9,10]. In addition, we
examined squaraines [11] and pheophorbide a [12-15], a
chlorophyll derivative with a tetrapyrrolic macrocycle
which is active at a nanomolar concentration range,
comparable to that of verteporfin and temoporfin: two
well-known photosensitizers used in clinic [16,17]. How-
ever, like many other photosensitizers, pheophorbide a is
not very soluble in water, and this reduces PDT efficacy. A
group of potential photosensitizers that are completely
soluble in water are the cationic porphyrins TMPyP2
(called P2), with four 2-methypyridyl groups, and TMPyP4
(called P4), with four 4-methylpyridyl groups (Figure 1A).
Porphyrin P4 has been extensively studied for its capacity
to bind to an unusual nucleic acid conformation called
G-quadruplex, formed by DNA and RNA sequences com-
posed of blocks of guanines [18-21]. DNA and RNA G-
quadruplexes (G4-DNA and G4-RNA) are stabilized by
the stacking upon each other of at least two G-tetrads (a
planar arrangement of four guanines each forming two
Hoogsteen hydrogen bonds with the neighboring bases)
and by alkali metal ions (Na+ or K+) that coordinate to O6
of guanines and lie in the central cavity of the structure
[22]. Over the last decade G4-DNA and G4–RNA have
attracted interest of several researchers providing growing
evidence that these quadruplexes are involved in the regu-
lation of gene expression. Compared to double-stranded
DNA, single-stranded RNA is unconstrained and thus
prone to fold into complex secondary/tertiary structures
containing double-stranded and G-quadruplex elements.
A bioinformatic study by Huppert et al. [23] revealed that
Figure 1 Structure and physical properties of the cationic porhyrins. (A) Structure of cationic porphyrins 5,10,15,20-tetra(N-methyl-4-pyridyl)
porphin (TMPyP4 or P4); 5,10,15,20-tetra(N-methyl-2-pyridyl)porphin (TMPyP2 or P2) and 5,10,15-tri(N-methyl-4-pyridyl)20(N-C14H29)-4-pyridyl)
porphin (C14); (B) DMA assay to determine the singlet oxygen quantum yield of porphyrins P2, P4 and C14. Full lines are the best-fit of experimental
points to first order decay equation y = exp(-kt). Irradiation was performed with 60 mW lamp. Fluorescence quantum yield data are from [34];
(C) Singlet oxygen and fluorescence quantum yield values.
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about 3000 5′-UTR of the human transcriptome contains
one or more G-quadruplex motifs. This brought the
authors to the conclusion that these tertiary structures
should regulate translation. They also demonstrated that
an RNA quadruplex-forming sequence within the 5′-UTR
of the NRAS transcript inhibited translation in vitro [24].
Ever since, there has been a growing literature on the
possible functions of RNA G-quadruplexes [25-27]. As
G4-RNA can indeed inhibit translation, the use of small
molecules to inhibit the function of mRNA looks quite
attractive [28].
In our study we focus on bifunctional G4 RNA-interacting
agents, i.e. molecules capable not only to bind to RNA
G-quadruplexes with a high affinity but also to generate
singlet oxygen (1O2) upon irradiation. In most human
cancers the RAS-MEK-ERK pathway that controls pro-
liferation is hyperactive [29,30]. The activator of this
pathway is protein RAS which is expressed by the ras genes
(KRAS, NRAS and HRAS). These genes are characterized
by the presence in the 5′ end of mRNA of a guanine rich
untranslated region (5′-UTR) containing quadruplex-
forming motifs which can serve as targets for small mol-
ecules with photosensitizing properties. Of particular
interest is KRAS, as it contains a 192-nt 5′-UTR with
45% guanines that can fold into a cluster of G4-RNA
structures and is in principle capable of providing mul-
tiple binding sites for cationic porphyrins [18-21]. The
5′-UTR of NRAS also harbors a G-rich motif forming a
very stable G-quadruplex structure.
Against this background we have hypothesized a new
strategy to down-regulate in cancer cells the mitogenic
RAS/MEK/ERK pathway [31]. We reasoned that the
porphyrins delivered to the cells should bind to mRNA,
in particular at G-rich quadruplex-forming sequences in
the 5′-UTRs of the ras genes. Upon irradiation, the por-
phyrins mediate a photoprocess leading to the degrad-
ation of mRNA, inhibition of ERK pathway and cell
proliferation. This therapeutic approach has been tested
in murine amelanotic melanoma B78-H1 cells both
in vitro (cell cultures) and in vivo (B78-H1 melanoma
cells transplanted in C57/BL6 mice). B78-H1 melanoma
cells derive from the B16 clone and have an activated
RAS/MEK/ERK pathway [32]. As bifunctional photosensi-
tizing agents we tested the cationic porphyrins tetra-meso
(N-methyl-4-pyridyl) porphine (called P4) and C14-alkyl
derivative tri-meso(N-methyl-4-pyridyl), meso(N-tetrade-
cyl-4-pyridyl) porphine (called C14). As a control, we used
the positional isomer tetra-meso(N-methyl-2-pyridyl) por-
phine (called P2), which does not bind to G4-RNA. In the
following we demonstrate that the cationic porphyrins
C14 and P4 strongly inhibit the growth of melanoma cells
both in vitro and in vivo. This anticancer effect correlates
with the capacity of these porphyrins to bind to the G-rich
region of mitogenic ras genes.
Results and discussion
Singlet oxygen generation by porphyrins C14, P4 and P2
The structures of porphyrins C14, P4 and P2 are shown in
Figure 1A. Due to their cationic charges they are very sol-
uble in aqueous solutions and obey the Lambert-Beer law
over a wide concentration range (not shown). Their cap-
acity to generate 1O2 was examined by the 9,10-dimethy-
lantracene (DMA) photobleaching assay [33]. DMA is a
fluorescent dye [λex = 375 nm, λem = 436 nm] that reacts
selectively with 1O2 to form a non-fluorescent endoperox-
ide derivative. An equimolar solution of DMA and por-
phyrin (10 μM each) was irradiated with a lamp (60 mW)
for different periods of time up to 1000 s and the residual
fluorescence was recorded between 380 and 550 nm.
The residual fluorescence was plotted as a function of
time and the experimental curve was best-fitted to a
first order decay equation y = exp (-k⋅t) where k (s-1)
is the rate constant and t the time(s) (Figure 1B). We
obtained k = 0.0058 ± 0.0004 s-1 for P4 and C14 and
k = 0.0021 ± 0.0006 s-1for P2. Considering that the quantum
yield of singlet oxygen generation (ϕΔ) of P4 was reported
to be 0.51 [34], we found that the ϕΔ of C14 and P2 were
respectively 0.51 and 0.18 (Figure 1C). It is worth noting
that porphyrin P2, being non planar due to steric clashes
between the 2-methyl-pyridyl groups and the 3-pyrrol
hydrogens, shows a lower ϕΔ.
Cellular uptake and phototoxicity of the cationic
porphyrins
The uptake of the cationic porphyrins by melanoma B78-
H1 cells has been investigated by FACS, taking advantage
of the fact that the porphyrins emit red fluorescence when
they are excited at 488 nm. Figure 2A shows a typical
FACS analysis of B78-H1 cells treated with 10 μM porphy-
rins for 2, 4, 8 and 24 h. As observed with human Panc-1
cells [31], C14 is taken up by melanoma cells more effi-
ciently than P2 or P4. After an incubation of 24 h, the
fluorescence of the cells treated with C14 is 25 and
50-fold higher than that observed with P4 and P2,
respectively. The data show that the addition to P4 of
the lipophilic chain significantly enhances the cellular
uptake.
The photoactivity of the porphyrins in B78-H1 cells
(24 h after delivery) has been evaluated by resazurin as-
says (Figure 2B). Without irradiation the porphyrins are
not cytotoxic (not shown), but when they are irradiated
with a halogen lamp at a fluence of 7.2 J/cm2, C14 and
P4 decrease the metabolic activity of the cells, at con-
centrations < 1 μM, while P2 shows some bioactivity
only at concentrations > 20 μM. A dose-response assay is
shown in Figure 2B. From these plots we estimated IC50
values of about 10 and 200 nM for C14 and P4 and
30 μM for P2. These values correlate with the different
uptake of the three porphyrins.
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The impact of the photoactivated porphyrins on the
clonogenic growth of B78-H1 melanoma cells was
also examined (Figure 3A). The cells treated with the por-
phyrins were seeded in plates and after an incubation of
7 days the colonies were stained with methylene blue. The
data show that the untreated cells formed colonies uni-
formly distributed in the plate (control). In contrast, the
cells treated with P4 and light (7.2 J/cm2) showed ~30% re-
duction in the number of colonies, while C14/light com-
pletely arrested the clonogenic growth. In contrast,
porphyrin P2/light did not have any inhibitory effect on col-
ony formation.
As a next step, the inhibition of proliferation and mi-
gration of B78-H1 cells caused by the cationic porphy-
rins was assessed by the scratch-wound healing assay.
This assay is based on the assumption that a denuded
area created in a plate (80% confluent) will quickly heal
thanks to proliferating and migrating cells. But as soon
as proliferation and migration are inhibited by the ef-
fector molecules, the cells will lose their healing capacity
and the area will remain denuded. Figure 3B reports a
typical experiment showing that B78-H1 cells untreated
or treated with P2 and light are able to heal the wound
in 24 h. Instead, when the cells are treated with an IC50
dose of P4 or C14 and light, they are not able to grow
and migrate with a sufficient rate to cover the denuded
area.
Having established that photoactivated P4 and C14
arrest proliferation, we asked if this effect was due to
apoptosis. An early event occurring in apoptosis is the
translocation of phosphatidylserine from the inner to the
outer leaflet of the plasma membrane, thus exposing it
to the external cell environment. Annexin V, a phospha-
tidylserine recognizing protein labeled with FITC, can
be used to detect this event by FACS. Early apoptosis
and late apoptosis/necrosis can be distinguished by
using annexin V and propidium iodide (PI) together
(Figure 4A). The percentage of apoptotic/necrotic cells
is reported in Table 1. It can be seen that C14 (10 nM)
strongly induces apoptosis (43%) and necrosis (38%) in
the melanoma B78-H1 cells, whereas P4 (250 nM) ap-
pears less efficient in triggering apoptosis (26%) and ne-
crosis (11%). The treatment with P4 produces, however,
a larger amount of cell debris than with C14 (18%
against 9%). From this experiment we concluded that
C14 and P4 promoted in melanoma cells both apoptosis
and necrosis and not only necrosis as previously found
with fibrosarcoma cells [35].
Figure 2 Uptake and metabolic activity of the cationic porphyrins. (A) FACS analyses of B78-H1 cells treated with 10 μM porphyrin. The
fluorescence associated to the cells (Ex 420 nm, Em 650–720 nm), was detected at 2, 4, 8 and 24 h after drug delivery; (B) % Metabolic activity of
B78-H1 cells treated with increasing amounts of porphyrin. 24 h after porphyrin delivery the cells have been irradiated with a halogen lamp at
the fluence of 7.2 J/cm2. A resazurin assay was carried out 24 h after irradiation. Experiments have been performed in triplicate, a Student T-test is
reported * = P < 0.01.
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To confirm the presence of apoptosis in B78-H1 cells
treated with the porphyrins, we measured by immuno-
blotting the cleavage of poly-(ADP ribose)-polymerase
(PARP-1) by caspases, as this is considered one of the best
markers for apoptosis [36]. In keeping with annexin/PI,
Figure 4B shows that P4 and C14 induced the cleavage of
PARP-1, while P2 did not. The extent of cleavage is pro-
portional to the percentage of apoptotic cells found by
FACS. Indeed, the cells treated with C14 showed 43%
apoptosis and ~50% PARP-1 cleavage, while those treated
with P4 had 26% apoptosis and ~10% PARP-1 cleavage.
Given the strong impact on clonogenic growth and
mobility caused by P4 and C14 in B78-H1 melanoma
cells, we asked whether these molecules are also able
to inhibit the growth of a B78-H1 melanoma tumour
subcutaneously transplanted in mouse. To address this
question, we first had to know how the porphyrins dis-
tribute in the mouse body, in order to determine the
time point at which the porphyrins show a high accumu-
lation in the tumour after delivery.
Biodistribution of the cationic porhyrins
The time-dependent distribution of P2, P4 and C14 after
injection in the peritoneum (i.p.) of female C57/BL6
mice bearing a subcutaneous B78-H1 melanoma tumour
of about 6–8 mm was examined as previously described
Figure 3 Clonogenic and scratch-wound assays. (A) Clongenic growth of B78-H1 cells treated with porphyrin at concentration near the IC50: C14
(10 nM), P4 (250 nM). The cells have been treated with porphyrin /light and let to grow for one week. The colonies formed have been fixed, stained
with methylene blue and counted. The number of colonies (>50 cells) is reported below each plate. The experiment has been perfomed in duplicate;
(B) Scratch-wound assay of B78-H1 cells plated at density of 6 × 105 cells/well in a 6-well plate. After attachment, the cells were treated with 7.5 nM
C14, 250 nM P2 and P4. A denudated area was created across the diameter of the dish with a yellow tip. Cells were washed with PBS and
further incubated in complete medium. After light irradiation (7.2 J/cm2), pictures were taken by an epiluminescent microscope (at 10-fold
magnification) to evaluate the migration of the cells. The experiment has been perfomed in duplicate.
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[37]. Porphyrins P2 and P4 were injected (and not
treated with light) at a concentration of 30 mg/Kg, while
C14, due to its higher cytoxicity, was used at a concen-
tration of 9 mg/Kg. For each molecule three animals
were sacrificed at each time point: 1, 3, 6, 9 and 24 h
post-injection. The amount of porphyrin recovered from
the various organs was measured as described in
Materials and Methods and the percentage of injected
dose per gram of organ (% ID/g) was determined and re-
ported in Figure 5. At 1, 3 and 6 h post-injection, the
porphyrins were detected in all the organs, except in the
brain. It is noteworthy that the amount of injected dose in
the tumour is higher than in normal tissues, except liver
and kidneys. Surprisingly, P4 showed a higher tumour ac-
cumulation than C14 (at 9 h after delivery % ID/g P4 ~ 2.5
versus % ID/g C14 ~ 0.9). It is possible that the alkyl group
reduces the capacity of C14 to diffuse from the peritoneus.
Indeed, the presence of C14 in the intestine is greater than
that of P4, at 3, 6 and 9 h post injection. The amount of
P2 in the organs is relatively low, and this correlates with
the low cellular uptake of this molecule.
The presence of C14 and P4 in liver, duodenum and
blood (not shown) up to 3 h post-injection suggests
that the porphyrins are recycled via the enterohepatic
pathway, but at higher time points, the urinary output
Figure 4 Annexin V-propidium iodide and PARP-1 cleavage assays. (A) Annexin V-propidium iodide assay of B78-H1 cells treated with 250
nM P2 or P4 and 10 nM C14. The proportion of cell population in apoptosis and necrosis is reported in Table 1. Before the FACS analysis the cells
have been treated with porphyrin and light (7.2 J/cm2). The experiment has been performed in triplicate; (B) Levels of PARP-1 and β-actin in
B78-H1 cells untreated or treated with 80 and 150 nM P2 and P4, 7.5 nM C14. The Western blots show the cleavage of PARP-1.
Table 1 Percentage of normal, apoptotic and necrotic
B78-H1 cells treated with P2, P4 or C14
Porphyrin % N T§ % Ap C§ % Ne C§ % Debris
NT 91 4 2 3
P2& 77 11 5 7
P4& 45 26 11 18
C14& 10 43 38 9
&P2 and P4 used at 250 nM, C14 used at 10 nM; §NT = untreated cells;
Ap C = apoptotic cells; Ne C = necrotic cells.
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prevails over the bile-gut recycling. Furthermore, the
fact that the porphyrines are practically not found in
the spleen, suggests that their elimination through the
reticolo-endothelial system is limited, contrarily to what
has been observed with more hydrophobic photosensi-
tizers [38].
Porphyrins P4 and C14 reduce tumour growth and
increase the mouse median survival time
To evaluate in vivo the anticancer property of P2, P4 and
C14, C57/BL6 mice with a subcutaneous B78-H1 mela-
noma tumour of about 6–8 mm were randomized into
groups of 8 animals each (the animals were prepared as
reported in Materials and Methods). In Figure 6A we re-
port the results obtained with P2 and P4. Group 1 was un-
treated, groups 2 and 3 were i.p. injected with P2 (30 mg/
Kg) and P4 (30 mg/Kg), respectively, groups 4 and 5 were
injected with P2 (30 mg/Kg), P4 (30 Kg/mg) then irradi-
ated at the Q-1 band (620–690 nm) with a diode laser at
660 ± 5 nm (fluence of 193 J/cm2), i.e. in the optical thera-
peutic window where light is harmless and shows its max-
imum depth of tissue penetration, as previously described
[37,39] (Additional file 1: Figure S1).
Irradiation was carried out ~7 h after delivery, when the
molecules showed a significant accumulation in the
tumour. We performed three porphyrin-light treatments,
Figure 5 Biodistribution of cationic porphyrins. Biodistribution of the porphyrins in various organs, after i.p. injection in C57/BL6 mice, bearing a
subcutaneous melanoma tumour, at the concentration of 30 mg/Kg P2 and P4 and 9 mg/Kg C14 (the mice were not irradiatiated). Ordinate reports
the percentage of injected dose (% ID). Distributions at 1, 3, 6, 9 and 24 h post injection are shown. Each bar is the average of 3 values (3 mice).
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at days 1, 7 and 14. The melanoma tumour grew with its
typical aggressiveness in the untreated mice (control), and
the mice showed a median survival time (m.s.t.) of about
43 days (Figure 6C). The treatment with P2 and P4 with-
out irradiation did not delay tumour growth and did not
increase the m.s.t. compared to control (Figure 6A,C). In
contrast, when the tumour was irradiated with the laser, a
significant delay in tumour growth was obtained with P4,
but not with P2, in keeping with the scarce uptake and
photosensitizing property of P2. As a further control, we
measured the rate of tumour growth when the mice were
irradiated in the absence of porphyrin, but no effect was
observed (not shown). The impact of P4 on tumour
growth was significant after the second treatment (day 7)
compared to both the untreated group (P < 0.001 by
ANOVA) and the group treated with P4 without irradi-
ation (P < 0.01). The Kaplan-Maier survival curves showed
that treatment with P4 and light increased the m.s.t. by ~
50% compared to the untreated group (from 40 to 60 days)
or the group treated with P2 and light (from 42 to 60 days)
(P < 0.01). In Figure 6B we show the behaviour of C14.
Porphyrin C14, at the concentration of 3 mg/Kg, inhibited
tumour growth and increased the m.s.t., as does P4 at
30 mg/Kg (Figure 6B,C). However, contrarily to P4, por-
phyrin C14 affected somewhat tumour growth, even in
the absence of irradiation. After the second PDT-
treatment (day 7), tumour growth in the groups treated
with C14/dark and C14/light was lower than in the un-
treated group (P < 0.05 and P < 0.01, respectively). The
dual effect of C14 appears more evident when the sur-
vival curves are examined. Compared to the untreated
group, C14 with and without irradiation increased the
median survival time from 40 to 60 and 52 days, re-
spectively (P < 0.01 for both groups). The likely mechan-
ism by which C14-dark reduces tumour growth will be
discussed in the next sections.
In summary, photoactivated C14 and P4 showed a re-
markable capacity to delay tumour growth in a melanoma
mouse model and to increase the survival of the treated
mice. Since the cationic porphyrins have a high affinity for
RNA G-rich sequences folded into G-quadruplex struc-
tures [31], we interrogated whether the antitumour acti-
vity of the porphyrins correlates with their binding to
RNA.
The cationic porphyrins bind to G-rich quadruplex-forming
sequences of mRNA
Previous studies have shown that mitochondria are major
intracellular targets for hydrophobic photosensitizers,
while cationic P4 seems to locate in the lysosomes [35]. So
Figure 6 Effect of porphyrins on melanoma tumour-bearing mice. (A) The mice with a melanoma tumour of about 8 mm were randomized
in 5 groups, each of 8 mice. Group 1 was untreated. Groups 2 and 3 were treated with 30 mg/Kg of P2 and P4; groups 4 and 5 were treated with
P2 and P4 (30 mg/Kg) then irradiated with a laser at 660 ± 5 nm (193 J/cm2), 9 h after delivery; (B) The mice were treated as follows. Group 1, untreated;
group 2, treated with 3 mg/Kg of C14; group 3, treated with 3 mg/Kg C14 and irradiated. Three treatments have been carried out: at days 1, 7 and 14. A
statistical analysis by ANOVA is reported. Each point of the curves is the average of 8 values (8 mice); (C) Kaplan-Meir showing the median survival time
of the treated mice compared to untreated (control) or mice treated with the porphyrin but not irradiated.
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far however, research on PDT did not focus on nucleic
acids as targets for photosensitizers. Considering that P4
and C14 accumulate in the cytoplasm and are cationic
in nature, they should interact with negatively charged
mRNA. There is a vast literature on porphyrin P4’s capa-
city to bind to DNA, in particular at G-rich quadruplex-
forming sequences occurring in the promoters of the
genes and at the ends of the chromosomes [40-47]. It
seems therefore reasonable to assume that if a quadruplex
structure is extruded by genomic G-rich sequences, these
structures should form more easily by unconstrained
single-stranded mRNA. We thus hypothesized that cat-
ionic porphyrins could bind to G4-RNA structures formed
by mRNA. Considering that in all stages of melanoma the
key signaling cascade stimulating proliferation is the RAS/
MEK/ERK pathway [48], we focused on the ras genes that
encode for protein RAS: the pathway activator [49]. The
ras genes show a high homology and their transcripts are
composed of six exons of which the exon at the 5′-end is
untranslated (5′-UTR) [50]. The 5′-UTR of KRAS has a
guanine content of 44% and five quadruplex-forming
sequences [31] (Figure 7A). Also NRAS [24] and HRAS in-
clude in their 5′-UTR G-rich sequences that can fold into
G4-RNA structures (Additional file 2: Figure S2). Quadru-
plex formation by mRNA sequences can easily be detected
by circular dichroism (CD). Typical CD spectra at various
temperatures for the KRAS sequence that we called utr-2
are shown in Figure 7B. The spectra clearly show that utr-
2 forms a parallel quadruplex with a TM of 54°C in
100 mM KCl [51]. In Table 2 we report the melting data
for some quadruplex-forming sequences of the ras genes.
These folded RNA structures are strong targets for cationic
porphyrins. Indeed, upon binding to the G4-RNA, the por-
phyrin’s Soret band undergoes strong hypochromic and
bathochromic effects (Figure 7C). Analyzing the data with
a simple binding equation (Sigma plot 11.0), we found that
the interaction between C14 and utr-2 G4-RNA is charac-
terized by a KD of ~ 5 × 10
-7 M.
The porphyrins mediate the photocleavage of mRNA
Next, we asked if mRNA is indeed degraded by the
photoactivated porphyrins. To address this question we
used three 32P-radiolabelled RNA fragments adopting
one of the possible conformations present in mRNA:
G4-RNA, duplex and single-stranded RNA. The three
radiolabelled RNA substrates were incubated with
Figure 7 G4-RNA formation within 5′-UTR of ras mRNAs. (A) Sequence of 5′-UTR in the murine KRAS mRNA. The quadruplex-forming sequences
(QFS) utr-1, utr-2, utr-3, utr-4 and utr-5 are boxed (strong QFS, full line; weak QFS broken line); (B) Typical CD spectra at various temperatures (from 20
to 90°C) of sequence utr2. Spectra have been collected at 20–30–40–50–60–70–80–90°C, using RNA 10 μM RNA, 50 mM Tris-HCl, pH 7.4, 100 mM KCl.
The ordinate reports the CD values in mdeg. Graph below shows the CD-melting curve of the utr-2 G-quadruplex; (C) UV-vis titration of porphyrin C14
(6 μM) with quadruplex utr-2. Inset shows the fraction of bound C14 as a function of G4-RNA. The experimental points have been best fitted to
a standard binding equation (Sigma Plot 11.0).
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porphyrin P2, P4 or C14 at r = 1, 3 and 6 (r = [porphy-
rin]/[RNA]) and irradiated with a halogen light at a flu-
ence of 7.2 J/cm2. The extent of photocleavage was
quantified and reported as histograms in Figure 8A. In the
absence of irradiation the porphyrins, even at r = 6, did
not promote any degradation (lane 2). Irradiation, in the
absence of porphyrin, did not affect RNA either (lane 14).
In contrast, when the samples were irradiated in the pres-
ence of the porphyrins, a photochemical process leading
to RNA degradation took place. The highest cleavage is
observed with the G4-RNA substrate (KRAS utr-2 at r = 3
and 6) (lanes 4 and 5), in keeping with the fact that P4 and
C14 show a higher affinity for the quadruplexes than the
duplex or single-stranded substrates [31].
Finally, we checked if the level of cellular mRNA is
actually reduced by the photoactivated porphyrins. By
quantitative RT-PCR, we found that 1 h after irradi-
ation P2 did not appreciably decrease the level of ras
transcript, while 15 or 30 nM C14 reduced KRAS
mRNA by ~50% compared to the control (cells tre-
tead with porphyrin but non irradiated). Porphyrin P4
also reduced the mRNA but only at the highest con-
centration (500 nM) (Figure 8B). These data are in
keeping with those obtained in Panc-1 cells and sup-
port our hypothesis that the cationic porphyrins tar-
get mRNA [31].
C14 exhibits also an intrinsic light-independent anticancer
activity
Several studies have hypothesized that the formation of
secondary or tertiary structures within the 5′-UTR of
mRNAs may have important functions in the regulation of
translation [25]. Since Balasubramanian and coworkers
have demonstrated that an RNA-forming sequence lo-
cated in NRAS mRNA inhibited translation in vitro, there
has been a growing interest in G4-RNA in the 5′-UTR of
mRNA [24]. To interfere with the translation process,
small molecules binding to G4-RNA in 5′-UTR of mRNA
have been used [28]. By stabilizing G4-RNA, these ligands
should impair the assembly and/or scanning of the 43S
ribosomal complex along mRNA. For example, quinolone
dicarboxamide derivatives and bisquinolinum compounds
showed translational inhibition [52,53]. The finding that
C14 without irradiation slows down tumour growth and
increases the median survival time by 35% (from 40 to
52 days) may be rationalized in terms of translation inhib-
ition. Due to its high cellular uptake, C14 accumulates in
the cytoplasm more than P4. Its binding to G4-RNA in
the 5′-UTR of ras mRNA (KRAS and NRAS) may inhibit
the translation process. Indeed, when we measured by im-
munoblotting the level of total protein RAS in B78-H1
cells treated with 1 or 5 μM P2, P4 and C14 (in the ab-
sence of light), we found that the protein was significantly
reduced by 5 μM C14, but not by P2 and P4 (Figure 9A).
The drop of RAS protein caused by C14 in the dark is
likely to be the cause of the observed decline of tumour
growth and increase of survival. Further investigation is
necessary for more insight into this point.
Photoactivated P4 and C14 inhibit the ERK pathway and
NF-kB
Our data showed that photoactivated P4 and C14 inhibit
the metabolic activity and the clonogenic growth of mel-
anoma B78-H1 cells by apoptosis and necrosis. We
therefore asked how this process is activated. Evidence
that the RAS/MEK/ERK signaling pathway plays a cen-
tral role in melanoma has been reported [54,55]. Protein
RAS initiates sequential phosphorylations leading to
P-ERK which, in turn, activates downstream proteins en-
hancing proliferation and survival. About 90% of melan-
oma tumours carries a high level of P-ERK [55]. Indeed,
we found that P-ERK in B78-H1 cells is aberrantly high,
though the ras genes are not mutated (Additional file 3:
Figure S3). This suggests that the ERK signaling pathway
can also be activated by perturbations of components
upstream of RAS [56]. Previous studies have demon-
strated that P-ERK induces the expression of various cy-
tokines and chemokines that are activators of NF-κB
[57,58]. In earlier work we found that in melanoma B78-
H1 cells NF-κΒ controls apoptosis via a loop involving
anti-apoptotic Snail and pro-apoptotic RKIP [59]. When
B78-H1 cells are treated with porphyrin P4 or C14 and
then irradiated, the resulting down-regulation RAS
expression is accompanied by a significant decrease
of the P-ERK and NF-κB (Figure 9B). A decrease of
NF-κB in B78-H1 cells brings about a repression of
anti-apoptotic Snail and an activation of pro-apoptotic
RKIP [59]. Apoptosis is thus activated, as documented
Table 2 Circular dichroism data of 5′-UTR sequences in mKRAS and mNRAS
Sequence5′→ 3′ TM[°C] CD KCl (mM)]
NRAS GGGGGCGGGGCGGGGCUGGACUGGG 74 Parallel 20
KRAS [utr1] GGCGGCUGAGGCGG 68 Parallel 100
KRAS [utr2] GGAAGGCGGCGG 54 Parallel 100
KRAS [utr3] GGCCUGAAGGCGGCGG 61 Parallel 100
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by PARP-1 cleavage and annexin V/PI assays. Consid-
ering the role of NF-κB in the tumourigenesis of mel-
anoma, combined treatments with cationic porphyrin/
light and NF-κB inhibitors should be effective against
melanoma [60].
Conclusions
In summary, we have documented that tetracationic, meso-
substituted porphyrins P4 and C14 are effective photosen-
sitizers for the photodynamic treatment of melanoma. A
previous study reported that P4 and C14 internalize in
human fibrosarcoma cells by endocytosis, causing cell
death by necrosis [35]. In melanoma B78-H1 cells,
photoactivated P4 and C14 behave in a more complex
way, as they cause cell death by apoptosis and necrosis.
Our data suggest that an intracellular target of the por-
phyrins is mRNA, in particular the G-rich quadruplex-
forming sequences located in the 5′-UTR of the mitogenic
ras genes. Although we cannot rule out that these mole-
cules can also bind to other gene transcripts, the cationic
porphyrins are particularly active in cancer cells showing a
RAS/MEK/ERK dependence, such as B78-H1 (Additional
file 3: Figure S3) and Panc-1 [31,61] cells. Evidence that
the porphyrins tightly bind to the G-rich quadruplex-
forming sequences in the KRAS transcripts is provided.
Due to their capacity to generate singlet oxygen upon
irradiation, P4 and C14 photocleave KRAS mRNA, thus
reducing the level of protein RAS and the activation of
downstream RAS/MEK/ERK and NF-κB pathways. This
photodynamic action against the ras transcripts is likely
to be responsible of the inhibitory effects on cell growth
seen in vitro and on tumour growth seen in vivo. In
priciple, this strategy has the advantage of minimizing
undesired secondary effects, as the photoprocess medi-
ated by the porphyrins leading to the degradation of
mRNA takes place only in the irradiated tumour. The
data reported are promising, however, to fully under-
stand the mechanism of tumour suppression in vivo,
further studies are necessary.
As for the two active porphyrins, we found that C14 is
a stronger anticancer drug than P4 as it: (i) internalizes
in the melanoma cells more than P4; (ii) inhibits the clo-
nogenic growth more than P4; (iii) acts through a light-
dependent mechanism (photocleavage of mRNA) as well
as a light-independent mechanism (blockade of transla-
tion through the stabilization of G4-RNA at the 5′-UTR
Figure 8 Photoactivated porphyrins degrade mRNA. (A) Photocleavage of RNA fragments from KRAS mRNA in three different conformations:
quaduplex utr-2; single stranded (ss-RNA) and double stranded (ds-RNA) after treatment with porphyrin P2, P4 or C14 at ratios 1:1, 1:3 and 1:6 and
light (7.2 J/cm2). The histograms show the percentage of clevage. Untreated RNA (lane 1), RNA treated with porphyrin only (lane 2), RNA treated
with light only (lane 14), RNA treated with both porphyrin and light (lanes 3–13); (B) Quantitative RT-PCR showing the level of KRAS mRNA in
B78-H1 cells after treated with porphyrin P2, P4 (250 and 500 nM) and C14 (15 and 30 nM) and light (7.2J/cm2). RT-PCR analysis performed 1 h
after irradiation. The experiment has been carried out in triplicate.
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of the ras genes). Indeed, C14 at 3 mg/Kg produces in vivo
the same effect as P4 does at 30 mg/Kg. By improving the
biodistribution of C14, for instance by incorporating the
molecule in nanoparticles to exploit their enhanced per-
meability and retention (EPR) effect, this cationic porphy-
rin may have a great potential in the cure of melanoma
skin tumours.
Methods
Porphyrins and oligonucleotides
Porphyrin tri-meso (N-methyl-4-pyridyl), meso (N-tetra-
decyl-4-pyridyl) porphine (TMPyP4-C14) was obtained
from Frontier Scientific Inc, Logan, UT, U.S.A, while
tetra-meso (N-methyl-4-pyridyl) porphine (TMPyP4) and
tetra-meso (N-methyl-2-pyridyl) porphine (TMPyP2) were
purchased from Porphyrins Systems (Lubeck, Germany).
They have been dissolved in water and conserved in
aliquots of 0.5 mM at −80°C. The stability in aqueous
solution of the porphyrins was checked by measuring
its UV-Vis spectrum at intervals of days. The RNA oli-
goribonucleotides, HPLC purified, have been purchased
from Microsynth (CH). The samples were conserved
at −80°C in 100 μM aliquots in water.
UV spectroscopy and circular dichroism
UV-vis spectra have been obtained with a Jasco V-530
UV/VIS spectrophotometer. CD spectra have been col-
lected with a JASCO J-600 spectropolarimeter equipped
with a thermostatted cell holder. RNA samples in 50 mM
Tris-HCl, pH 7.4, 100 mM KCl were 10 μM. The spectra
were recorded in 0.5 cm quartz cuvette at increasing
temperature. Ordinate is expressed in mdeg.
Cell culture, metabolic activity assay and PDT treatment
In this study we used murine amelanotic melanoma
B78-H1 cells. The cells were maintained in exponential
growth in Dulbecco’s modified eagle’s medium contain-
ing 100 U/ml penicillin, 100 mg/ml streptomycin,
20 mM L-glutamine and 10% fetal bovine serum
(Euroclone, Milano, Italy). The cells were seeded in a
96-well plate at a density of 5 × 103 cells/well. The follow-
ing day they have been treated with the porphyrins in the
dark and after 24 h, irradiated with metal halogen lamp
with an irradiation of 8 mW/cm2 for 15 min (fluence 7.2 J/
cm2). 24 h after irradiation the metabolic activity was deter-
mined by the resazurin assay following the manufacturer’s
instructions (Sigma–Aldrich, Milan, Italy). The fluorescence
Figure 9 Effect of porphyrins on protein RAS and ERK pathway. (A) Immunoblots showing the expression level of protein RAS in melanoma
B78-H1 cells 24 h after treatment with porphyrins P2, P4 and C14 (1 and 5 μM) without irradiation. C14 at 5 μM reduces the level of protein RAS
through a light-independent mechanism; (B) Immunoblots showing the levels of RAS, ERK, P-ERK, NF-κB and β-actin in untreated or porphyrin/
light treated B78-H1 cells, 24 h after light treatment.
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was measured with a spectrofluorometer Spectra Max
GeminiXS (Molecular Devices, Sunnyvale, CA). The data
are presented as the percentage of metabolic activity com-
pared to untreated cells. The data are the average of at least
three independent experiments.
The protocol for PDT was the same for each type
of experiment. B78-H1 cells have been plated, the day
after the cells have been treated with porhyrins. Then,
after 24 h the cells have been irradiated with the
halogen lamp (fluence 7.2 J/cm2). As P2 is an isomer
of P4 and does not produce any effect on the cells,
this molecule was used at the same dose of P4, as a
negative control.
Clonogenic assay
B78-H1 cells have been treated with porphyrin/light and
seeded in 60 mm Petri dish, at a density of 5 × 103 cells.
After one week of growth, the colonies were fixed and
stained with 2.5% methylene blue in 50% ethanol for
10 min. The images were obtained by Gel DOC 2000
Bio-Rad (Milan, Italy). The stained colonies (>50 cells)
have been counted by an Image Scanner equipped with
Image Quant TL software (Amersham Biosciences). The
experiment was performed in duplicate.
Annexin V-propidium iodide assay
Apoptosis was assessed by annexin V, a protein that
binds to phosphatidylserine (PS) residues, which are
exposed on the cell surface of apoptotic cells. B78-H1
cells were seeded in a 6-well plate at density of 5 ×
105 cells/well. After one day, the cells were treated
with P2, P4 or C14 for 24 h and irradiated for
15 min with a halogen lamp (7.2 J/cm2). After light
activation, cells were washed with PBS, trypsinized,
and pelleted. Pellets were suspended in 100 μL Hepes
buffer added with 2 μL of annexin V and 2 μL of
propidium iodide, PI (annexin-V FLUOS Staining kit,
Roche, Penzberg, Germany) and incubated for 10 min
at 25°C in the dark. Cells were immediately analyzed
by FACS (Becton-Dickinson, San Jose, United States).
A minimum of 104 cells per sample were acquired in
list mode and analyzed using Cell Quest software.
The cell population was analyzed by FSC light and
SSC light. The signal was detected by FL1 (annexin
V-FITC) and FL-2 (PI). The dual parameter dot plots
combining annexin V-FITC and PI fluorescence show
the vial cell population in the lower left quadrant, the
early apoptotic cells in the lower right quadrant, and
the late apoptotic or necrotic cells in the upper right
quadrant.
The scratch-wound assay
The cells were seeded in a 6-well plate at a density of
6 × 105 cells/well and grown for 24 h to 80% confluence.
A denuded area was created across the diameter of
the dish by a yellow tip. After treatment with the por-
phyrin and light, the cells were washed with PBS and
further incubated in a complete medium. Pictures
were taken with an epiluminescent microscope Leica
DMI6000B (Leica Microsystem, Heidelberg, Germany)
at a 10-fold magnification to evaluate cell growth and
migration [62].
Immunoblotting analysis
Total protein lysates (30 μg), obtained 24 h after porphy-
rin/light treatment (see above), were run on 12% SDS-
PAGE and blotted to a nitrocellulose membrane 70 V for
2 h. The membrane was treated for 1 h with PBS-0.01%
Tween (Sigma-Aldrich, Milan, Italy) containing 5% dry
non-fat-milk and incubated overnight at 4°C with the pri-
mary antibodies: mouse monoclonal c-KRAS Oncogene,
(Cell Signaling, Merck Millipore, Darmstadt, Germany)
diluted 1:40, rabbit polyclonal anti-NF-κB p65 (C-20,
sc-372 Santa Cruz Biotechnology, Santa Cruz, CA), di-
luted 1:1000; rabbit polyclonal anti-ERK (p44/42 MAPK,
9102, Cell Signalling, Danvers MA) diluted 1:1000; rabbit
polyclonal anti-P-ERK (phospho-p 44/42 MAPK, 9101Cell
Signalling, Danvers MA) diluted 1:1000; rabbit polyclonal
anti-PARP (9542, Cell Signalling, Danvers MA) diluted
1:1000. β-Actin was used as an internal control. It was de-
tected with a mouse monoclonal anti β-actin (Ab-1, CP01,
Calbiochem, Merck Millipore, Darmstadt, Germany ),
diluted 1:10000. The membranes were incubated for 1 h
with a secondary antibodies, either anti-rabbit IgG di-
luted 1:5000 (Calbiochem, Merck Millipore, Darmstadt,
Germany) or anti-mouse IgM, diluted 1:5000 (Calbiochem,
Merck Millipore, Darmstadt, Germany). Each secondary
antibody was coupled to horseradish peroxidase (HPR). For
the detection of the proteins, we used ECL (enhanced
chemiluminescence) reagents (Super Signal®West PICO,
and Super Signal®West FEMTO, Thermo Fisher Scien-
tific Pierce, Rockford, USA). The exposure depended on
the type of antibody and varied between 30 seconds to
5 min. The protein levels were quantified by Image
Quant TL Version 2003 software (Amersham).
RNA extraction and quantitative RT-PCR
B78-H1 cells have been plated in a 96-well plate (25000
cells/well). After 24 h, the cells have been treated for fur-
ther 24 h with C14 (15 and 30 nM), P4 and P2 (250 and
500 nM). For each porphyrin concentration, we prepared
6 samples: three have been irradiated (15 min, halogen
lamp, fluence 7.2 J/cm2) and 3 were not. 1 h following
irradiation, total RNA was extracted from each sample
with 20 μl of iScript™ RT-qPCR Sample Preparation
Reagent (Bio-Rad).
For cDNA synthesis mixtures containing 1.25 μl of
RNA, 1× buffer, 0.01 M DTT (Invitrogen, Milan, Italy),
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1.6 μM primer dT (MWG Biotech, Ebersberg, Germany;
d(T)16), 1.6 μM Random examers (Microsynth), 0.4 mM
of each dNTP (Euroclone, Pavia, Italy), 0.6 units/μl
RNase OUT, and 8 units/μl of Maloney murine leukemia
virus reverse transcriptase (Invitrogen, Milan, Italy) were
prepared and incubated for 1 h at 37°C. Real-time PCR
reactions were performed with 1× Kapa Sybr Fast qPCR
kit (Kapa Biosystems), 100–250 nM of each primer, 1 μl
of reverse transcription reaction. The PCR cycle was:
3 min at 95°C, 40 cycles 10 s at 95°C, 30 s at 60°C for
KRAS and 65°C for hypoxanthine-guanine phosphoribo-
syltransferase (HPRT) and β2-microglobulin (β2M) with
CFX 96 real-time PCR controlled by Bio-Rad CFX
Manager 3.0 (Bio-Rad). The sequences of primers used for
amplifications are: for KRAS (Accession n. BC 010202)
mKRAS for 5′-GCTCAGGAGTTAGCAAGGAG bases
570-89 and mKRAS back 5′-GTATTCACATAACTGTAC
ACCTTG 730-753 (200nM); for β2M (NM_009735)
mβ2M for 5′-GTCTCACTGACCGGCCTGTATG 91-112
and mβ2M rev 5′-CCCGTTCTTCAGCATTTGGATTTC
220-43 (100nM); for HPRT (NM_013556) mHPRT for
5′-GTGTTGGATACAGGCCAGACTTTG 599-622 and
mHPRT rev 5′-ATCAACAGGACTCCTCGTATTTGC
765-88 (250nM). KRAS expression is normalized with
HPRT and β2M.
Photocleavage experiment
32P-labelled RNA fragments in quadruplex, duplex or
single-strand conformations have been incubated over-
night in 50 mM Tris HCl, pH 7.5, 100 mM KCl, 4°C.
Mixture of 5 nM RNA and porphyrin (1:1; 1:2; 1:6) were
incubated for 2 h at room temperature, then irradiated
with the halogen lamp for 20 minutes. After irradiation
the samples were denaturated and run in a 20% acryl-
amide gel, 7 M urea and 1 × TBE, at 55°C. The gels were
dried and exposed to autoradiography.
Organ extraction and porphyrin biodistribution in mice
with a B78-H1 tumour
The amount of porphyrin in the various organs was de-
termined using the method of Villanueva and Jori [37].
The molecules were solubilized in saline solution and
administered by intraperitoneal injection (i.p.) at the
mice (P2 and P4, 30 mg/kg; C14, 9 mg/kg). The animals
were sacrificed by cervical dislocation at different time
points after administration (1, 3, 6, 9 and 24 h) (three
mice for each time point). The organs (brain, kidney,
duodenum, spleen, lung, liver, tumour and blood) were
collected and homogenized in MeOH:DMSO (4:1 v/v).
The homogenates were centrifuged and the amount of
P2, P4 or C14 present in the supernatant was measured
by fluorescence (Ex. 420 nm, Em. 450 to 750 nm). We
did not observe any interference from other compounds
present in the extracts. The amount of porphyrin in the
various organs was determined by means of a calibration
curve, which was obtained by plotting the fluores-
cence intensity against porphyrin concentration, using
standard calibration porphyrin solutions. The curve
was linear in the range from 0 to 2 μg/100 mg tissue
with a correlation coefficient r2 = 0.9994. Blood sam-
ples were taken from the left ventricle and centrifuged
at 3000 g for 10 min to separate the plasma and stored
at −80°C. Serum samples were diluted with defined
volumes of 2% SDS so that the absorbance of cationic
porphyrins at 423 nm was lower than 0.1 and analysed
at the spectrofluorimeter. The porphyrin amounts
were determined by interpolation on a standard curve
plotted with known amounts of cationic porphyrins in
2% SDS, and reported in terms of mg/mg tissue or
mg/ml of serum. The assay was highly reproducible
with errors <8%.
Antitumour activity of the cationic porphyrins
Female 6-week old C57/BL6 mice were obtained from
Harlan-Nossan (Italy) and were maintained in a con-
ventional animal house for 2 weeks. All procedures
with animals were carried out in accordance with the
National Health Institute Guide for the Care and Use
of Laboratory Animals and approved by the Institu-
tional Animal Care Committee at the University of Tri-
este (approval number given by the Italian Ministry of
Health: 6/2011-B). In particular every effort was made
to avoid unnecessary pain to the animals. The mice,
weighing 20 g, were implanted into the upper flank by
subcutaneously injection with 2 × 106 B78-H1 amela-
notic melanoma cells harvested from a cell culture.
After 2 weeks the tumours reached a size of 6–8 mm
(along the largest diameter) and the mice were ran-
domized into groups of 8 mice each and injected intra-
peritoneally with the porphyrins (P2 and P4, 30 mg/Kg;
C14, 3 mg/Kg). About 7 h after injection, when the
porphyrins were present in the tumour in significant
amounts, the mice were anesthetized with Zoletil® +
Xylazine (15 mg/kg + 5 mg/kg; i.p.), shaved in the
tumour area and irradiated with a laser BWN-660-60E
[B&WTEK, Inc, Newark, DE, USA] at 660 ± 5 nm, flu-
ence of 193 J/cm2. Three porphyrin/light treatments
have been carried out at days 1, 7 and 14. The mice
were examined every 2 days for changes in weight, ap-
pearance of side effects or signs of sickness. The size of
the tumour was measured every 2–3 days by a caliper.
The mass (mg) of the tumour was calculated assuming
a tumour density of 1 and a tumour volume given by
π/6 · a2 · b where a and b are the shorter and larger
axes (cm), respectively. The median survival time is de-
fined as the animal’s life spanning from the inoculation
of tumour cells till death.
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Singlet oxygen quantum yield of the cationic porphyrins
determined by DMA
The quantum yield (ϕΔ) of 1O2 generation by the pho-
toexcited triplet state of the porphyrins was measured
by 9,10-dimethyl-anthracene (DMA). Upon reacting with
1O2, DMA is transformed in the non-fluorescent 9,10-en-
doperoxide. As this reaction occurs with a high degree of
specificity and with 100% chemical quenching of the fluor-
escence [33], the amount of DMA modified by the photo-
activated porphyirn is a quantitative estimate of singlet
oxygen generation. In a typical experiment 1 ml DMA
(10 μM) was added to 1 ml porphyrin (10 μM) in a quartz
cuvette and the resulting solution irradiated with a lamp
(60 mW) for increasing times, under gentle magnetic stir-
ring. In a typical experiment a solution containing DMA
and porphyrin (1:1, 10 μM) was irradiated for different
periods of time after which the residual fluorescence was
recorded between 380 and 550 nm. The residual fluores-
cence was best-fitted to a first order decay equation y =
exp (-k⋅t) where k (s-1) is the rate constant and t the time
[s]. We obtained k for for P4, C14 and P2. Considering
that the quantum yield of singlet oxygen generation (ϕΔ)
of P4 was reported to be 0.51 [34], the singlet oxygen
quantum yield was obtained by the relation:
k P4ð Þ : k porhyrinð Þ ¼ ϕΔ P4ð Þ : ϕΔ porhyrinð Þ
where k (P4) and k (porphyrin) are determined
experimentally.
Statistical analysis
The primary growth tumour analyses were performed by
the Graph Pad PRISM. Tabled values are group means ±
SE (standard error). Data were subjected to the appro-
priate factorial ANOVAs assessing significance against
an alfa-level p < 0.05. When the individual effect of the
treatments and the interaction between the independent
variables in a 2 × 2 ANOVA was significant, the data
were subjected to post hoc Tukey test for significance of
the differences in the mean values. All analyses were
performed using standard procedures implemented in
the Systat package (SYSTAT Inc., Evanston, IL). The sur-
vival analysis was performed using the Kaplan-Meier
curve (SPSS 11.0 for Windows 2000 software), and the P
values were calculated by long-rank test.
Additional files
Additional file 1: Figure S1. Dimethylanthracene assay shows singlet
oxygen production by the cationic porphyrins irradiated with a laser at
660 nm.
Additional file 2: Figure S2. G4-RNA formation in the 5’-UTR of KRAS
and NRAS mRNAs.
Additional file 3: Figure S3. Melanoma B78-H1 cells are characterized
by a hyperactive RAS/MEK/ERK pathway.
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